Business
CANTAB Recruit release
CANTAB Recruit release.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 7160U Cambridge Cognition Holdings PLC 11 April 2016 \n\n11 April 2016\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nOnline recruitment platform to accelerate pharmaceutical development\n \nThe neuroscience and technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG) is launching its first web-based product, CANTAB Recruit, using the scientifically validated CANTAB® technology. This is expected to open the door for home-based cognitive testing at scale.\n \nCANTAB Recruit is an online patient recruitment portal for pharmaceutical and biotechnology companies to accelerate the identification of qualified clinical trial participants in high-need indications such as Alzheimer's disease. \n \nThe web-based platform promises to enrich clinical research by sensitively pre-screening patients using innovative, interactive and proven cognitive measures to reduce screen failure rates and save study sponsors substantial time and cost.\n \nThe launch of CANTAB Recruit follows the first showing on April 7th of the Company's new technology Cognition Kit™, the wearable platform that will enable doctors, scientists and the public to better understand and manage day-to-day brain health. \n \nWith CANTAB Connect, the cloud-based cognitive assessment system for clinical trials launched in 2014, and CANTAB Insight, the Company's Class II medical device for detecting the earliest signs of cognitive impairment, the Cambridge Cognition product portfolio now includes a range of multi-platform solutions for use throughout the drug development lifecycle and patient engagement.\n \nInitially, the focus for CANTAB Recruit will be in Alzheimer's disease clinical trials. Currently, around 35.6 million people worldwide have dementia, forecast by Alzheimer's Disease International to increase to 115.4 million - or one in 85 people - by 2050, with Alzheimer's disease accounting for around 75% of cases.1,2\n \nAs the Alzheimer's disease field moves towards prevention3, the challenge of bringing participants to research sites for early intervention trials has become a major bottleneck. Each new clinical trial, particularly those that target prodromal populations, may take as long as three years to complete enrolment, with screen-fail rates as high...